The transaction is sourced from an SEC EDGAR Form 8-K filing published on February 20, 2025. Based on the facts provided, the deal's status is pending regulatory approval.
On the financial advisory side, BofA Securities, Inc. is acting as exclusive financial advisor to FibroGen, the seller in this transaction, and is identified as the lead advisor in that capacity.
On the legal side, Ropes & Gray LLP is acting as legal advisor to FibroGen, paired with BofA Securities in the same source sentence describing the company's advisory team on this transaction. No financial or legal advisor to AstraZeneca, the acquirer, is identified in the facts provided.
Beyond confirming that this is a subsidiary or asset sale with a disclosed value of 160,000,000 dollars, no further detail on the specific assets or subsidiary interests being conveyed, or on any additional consideration structure such as royalties or milestone payments, is included in the facts available.
A number of elements of this deal remain undisclosed. No financial or legal advisor to AstraZeneca is named, and no detail is provided on the specific scope of the FibroGen China assets being sold beyond the 160,000,000 dollar disclosed value. The facts also do not specify an expected closing date or what regulatory approvals are required to complete the transaction.